Skip to main content
SpringerLink
Log in

Atezolizumab

Immune-mediated hepatitis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Li M, et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 126: 5088-5097, No. 23, 1 Dec 2020. Available from: URL: http://doi.org/10.1002/cncr.33165

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab. Reactions Weekly 1834, 45 (2020). https://doi.org/10.1007/s40278-020-87237-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-87237-6

Search

Navigation